Apellis Pharmaceuticals (APLS)

• Market cap: $2.1B
• 1 day: -3.36%
• 5 days: -6.23%
• 1 month: -13.61%
• 3 months: -39.05%
• 6 months: -40.48%
• Year to date: -49.64%
• 1 year: -59.47%
• 5 years: -44.96%
• 10 years: 19.03%
• Sector: Healthcare
• Industry: Biotechnology

About: Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.

Employees: 710

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

212% more call options, than puts

Call options by funds: $104M | Put options by funds: $33.5M

37% more repeat investments, than reductions

Existing positions increased: 97 | Existing positions reduced: 71

20% more capital invested

Capital invested by funds: $3.38B [Q3] → $4.04B (+$667M) [Q4]

5.73% more ownership

Funds ownership: 96.14% [Q3] → 101.87% (+5.73%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 6 [Q3] → 6 (+0) [Q4]

2% less first-time investments, than exits

New positions opened: 60 | Existing positions closed: 61

2% less funds holding

Funds holding: 261 [Q3] → 257 (-4) [Q4]

Research analyst outlook

13 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $18 8% upside
• Avg. target: $35 108% upside
• High target: $57 241% upside

13 analyst ratings

• positive: 6 46%
• neutral: 7 54%
• negative: 0 0%

Mizuho Graig Suvannavejh 42% 1-year accuracy 8 / 19 met price target	20% upside $20	Neutral Maintained	14 May 2025
Raymond James Ryan Deschner 91% 1-year accuracy 10 / 11 met price target	211% upside $52	Outperform Downgraded	9 May 2025
B of A Securities Tazeen Ahmad 29% 1-year accuracy 9 / 31 met price target	38% upside $23	Neutral Downgraded	9 May 2025
RBC Capital Luca Issi 20% 1-year accuracy 11 / 55 met price target	8% upside $18	Sector Perform Maintained	8 May 2025
Scotiabank Greg Harrison 32% 1-year accuracy 13 / 41 met price target	20% upside $20	Sector Perform Maintained	8 May 2025